AGC Biologics, a convergence of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics, will be integrated and newly branded as AGC Biologics. AGC Biologics, a provider of clinical and commercial manufacturing of therapeutic proteins, will offer contract development and manufacturing services to its clients from their state-of-the-art facilities in Seattle, WA and Berkeley, CA in the U.S.; Copenhagen, Denmark; Heidelberg, Germany; Chiba, Japan; and Yokohama, Japan. The company ...